Ratings MedPeer,Inc.

Equities

6095

JP3921240002

Delayed Japan Exchange 02:00:00 2024-05-02 am EDT 5-day change 1st Jan Change
676 JPY -1.60% Intraday chart for MedPeer,Inc. -1.74% -5.59%

Strengths

  • The company is in a robust financial situation considering its net cash and margin position.
  • With regards to fundamentals, the enterprise value to sales ratio is at 0.84 for the current period. Therefore, the company is undervalued.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

  • The company benefits from high valuations in earnings multiples.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Sector: Internet Services

1st Jan change Capi. Investor Rating ESG Refinitiv
-5.59% 96.03M -
+26.77% 434B
B
+18.99% 250B
D+
+12.44% 144B
A-
+17.31% 101B
C-
+24.59% 88.78B
B+
+57.56% 58.93B
B-
+15.09% 46.54B
C+
+4.39% 37.25B
B
+20.16% 35.9B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW